Search Results - "CHILD, J. Anthony"

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis by Morgan, Gareth J., Gregory, Walter M., Davies, Faith E., Bell, Sue E., Szubert, Alexander J., Brown, Julia M., Coy, Nuria N., Cook, Gordon, Russell, Nigel H., Rudin, Claudius, Roddie, Huw, Drayson, Mark T., Owen, Roger G., Ross, Fiona M., Jackson, Graham H., Child, J. Anthony

“…Thalidomide maintenance has the potential to modulate residual multiple myeloma (MM) after an initial response. This trial compared the effect of thalidomide…”
Get full text

Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials by Bradbury, Charlotte A., Craig, Zoe, Cook, Gordon, Pawlyn, Charlotte, Cairns, David A., Hockaday, Anna, Paterson, Andrea, Jenner, Matthew W., Jones, John R., Drayson, Mark T., Owen, Roger G., Kaiser, Martin F., Gregory, Walter M., Davies, Faith E., Child, J. Anthony, Morgan, Gareth J., Jackson, Graham H.

“…Newly diagnosed multiple myeloma (NDMM) patients treated with immunomodulatory drugs are at high risk of venous thromboembolism (VTE), but data are lacking…”
Get full text

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study by RAWSTRON, Andy C, CHILD, J. Anthony, ROSS, Fiona M, COOK, Gordon, JACKSON, Graham H, MORGAN, Gareth J, OWEN, Roger G, DE TUTE, Ruth M, DAVIES, Faith E, GREGORY, Walter M, BELL, Sue E, SZUBERT, Alexander J, NAVARRO-COY, Nuria, DRAYSON, Mark T, FEYLER, Sylvia

“…To investigate the prognostic value of minimal residual disease (MRD) assessment in patients with multiple myeloma treated in the MRC (Medical Research…”
Get full text

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction by Rawstron, Andy C., Gregory, Walter M., de Tute, Ruth M., Davies, Faith E., Bell, Sue E., Drayson, Mark T., Cook, Gordon, Jackson, Graham H., Morgan, Gareth J., Child, J. Anthony, Owen, Roger G.

“…The detection of minimal residual disease (MRD) in myeloma using a 0.01% threshold (10−4) after treatment is an independent predictor of progression-free…”
Get full text

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial by Morgan, Gareth J, Dr, Prof, Davies, Faith E, MD, Gregory, Walter M, Prof, Cocks, Kim, MSc, Bell, Sue E, DPhil, Szubert, Alex J, MSc, Navarro-Coy, Nuria, MPhil, Drayson, Mark T, MD, Owen, Roger G, MD, Feyler, Sylvia, MD, Ashcroft, A John, MD, Ross, Fiona, DPhil, Byrne, Jennifer, MD, Roddie, Huw, MD, Rudin, Claudius, MD, Cook, Gordon, MD, Jackson, Graham H, Prof, Child, J Anthony, Prof

“…Summary Background Bisphosphonates reduce the risk of skeletal events in patients with malignant bone disease, and zoledronic acid has shown potential…”
Get full text

Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels by Heaney, Jennifer L J, Richter, Alex, Bowcock, Stella, Pratt, Guy, Child, J Anthony, Jackson, Graham, Morgan, Gareth, Turesson, Ingemar, Drayson, Mark T

Get full text

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation by Morgan, Gareth J., Davies, Faith E., Gregory, Walter M., Russell, Nigel H., Bell, Sue E., Szubert, Alexander J., Coy, Nuria Navarro, Cook, Gordon, Feyler, Sylvia, Byrne, Jenny L., Roddie, Huw, Rudin, Claudius, Drayson, Mark T., Owen, Roger G., Ross, Fiona M., Jackson, Graham H., Child, J. Anthony

“…As part of the randomized MRC Myeloma IX trial, we compared an attenuated regimen of cyclophosphamide, thalidomide, and dexamethasone (CTDa; n = 426) with…”
Get full text

International Staging System for Multiple Myeloma by GREIPP, Philip R, SAN MIGUEL, Jesus, LAHUERTA, Juan J, LUDWIG, Heinz, MORGAN, Gareth, POWLES, Raymond, SHIMIZU, Kazuyuki, SHUSTIK, Chaim, SONNEVELD, Pieter, TOSI, Patrizia, TURESSON, Ingemar, WESTIN, Jan, DURIE, Brian G. M, CROWLEY, John J, BARLOGIE, Bart, BLADE, Joan, BOCCADORO, Mario, CHILD, J. Anthony, HAROUSSEAU, Jean-Luc, KYLE, Robert A

“…There is a need for a simple, reliable staging system for multiple myeloma that can be applied internationally for patient classification and stratification…”
Get full text

Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party by AUGUSTSON, Bradley M, BEGUM, Gulnaz, DUNN, Janet A, BARTH, Nicola J, DAVIES, Faith, MORGAN, Gareth, BEHRENS, Judith, SMITH, Alastair, CHILD, J. Anthony, DRAYSON, Mark T

“…Early mortality in multiple myeloma (MM) is usually attributed to combined effects of active disease and comorbid factors. We have studied early deaths in a…”
Get full text

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial by Morgan, Gareth J, Prof, Child, J Anthony, Prof, Gregory, Walter M, Prof, Szubert, Alex J, MSc, Cocks, Kim, MSc, Bell, Sue E, DPhil, Navarro-Coy, Nuria, MPhil, Drayson, Mark T, MD, Owen, Roger G, MD, Feyler, Sylvia, MD, Ashcroft, A John, MD, Ross, Fiona M, DPhil, Byrne, Jennifer, MD, Roddie, Huw, MD, Rudin, Claudius, MD, Cook, Gordon, MD, Jackson, Graham H, Prof, Wu, Ping, MSc, Davies, Faith E, MD

“…Summary Background Bisphosphonates are the standard of care for reducing the risk of skeletal-related events in patients with bone lesions from multiple…”
Get full text

Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests by Heaney, Jennifer L. J., Campbell, John P., Griffin, Anne E., Birtwistle, Jane, Shemar, Meena, Child, J Anthony, Gregory, Walter M., Cairns, David A., Morgan, Gareth, Jackson, Graham, Drayson, Mark T.

“…Summary This study aims to guide the integration of serum free light chain (sFLC) tests into clinical practice, including a new rapid test (Seralite®). Blood…”
Get full text

Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk by Broderick, Peter, Chubb, Daniel, Johnson, David C, Weinhold, Niels, Försti, Asta, Lloyd, Amy, Olver, Bianca, Ma, Yussanne P, Dobbins, Sara E, Walker, Brian A, Davies, Faith E, Gregory, Walter A, Child, J Anthony, Ross, Fiona M, Jackson, Graham H, Neben, Kai, Jauch, Anna, Hoffmann, Per, Mühleisen, Thomas W, Nöthen, Markus M, Moebus, Susanne, Tomlinson, Ian P, Goldschmidt, Hartmut, Hemminki, Kari, Morgan, Gareth J, Houlston, Richard S

“…Richard Houlston, Gareth Morgan, Kari Hemminki and colleagues report the results of a genome-wide association study of multiple myeloma. They identify two…”
Get full text

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results by MORGAN, Gareth J, DAVIES, Faith E, DRAYSON, Mark T, OWEN, Roger G, ROSS, Fiona M, RUSSELL, Nigel H, JACKSON, Graham H, CHILD, J. Anthony, GREGORY, Walter M, BELL, Sue E, SZUBERT, Alexander J, NAVARRO COY, Nuria, COOK, Gordon, FEYLER, Sylvia, JOHNSON, Peter R. E, RUDIN, Claudius

“…Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate for induction therapy prior to high-dose…”
Get full text

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen by de Tute, Ruth M, Rawstron, Andy C, Gregory, Walter M, Child, J Anthony, Davies, Faith E, Bell, Sue E, Cook, Gordon, Szubert, Alexander J, Drayson, Mark T, Jackson, Graham H, Morgan, Gareth J, Owen, Roger G

Get full text

Genetic Factors Underlying the Risk of Thalidomide-Related Neuropathy in Patients With Multiple Myeloma by JOHNSON, David C, CORTHALS, Sophie L, VAN NESS, Brian, CHILD, J. Anthony, SONNEVELD, Pieter, MORGAN, Gareth J, WALKER, Brian A, ROSS, Fiona M, GREGORY, Walter M, DICKENS, Nicholas J, LOKHORST, Henk M, GOLDSCHMIDT, Hartmut, DAVIES, Faith E, DURIE, Brian G. M

“…To indentify genetic variation that can modulate and predict the risk of developing thalidomide-related peripheral neuropathy (TrPN). We analyzed DNA from…”
Get full text

Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma by Yadav, Punit, Cockwell, Paul, Cook, Mark, Pinney, Jennifer, Giles, Hannah, Aung, Yu Sandar, Cairns, David, Owen, Roger G, Davies, Faith E, Jackson, Graham H, Child, J Anthony, Morgan, Gareth J, Drayson, Mark T

“…Renal impairment (RI) is common in multiple myeloma (MM) and is associated with poor survival. This study reports the associations between renal function and…”
Get full text

The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy by Boyd, Kevin D., Ross, Fiona M., Tapper, William J., Chiecchio, Laura, Dagrada, GianPaolo, Konn, Zoe J., Gonzalez, David, Walker, Brian A., Hockley, Sarah L., Wardell, Christopher P., Gregory, Walter M., Anthony Child, J., Jackson, Graham H., Davies, Faith E., Morgan, Gareth J.

“…Hemizygous deletion of 17p (del(17p)) has been identified as a variable associated with poor prognosis in myeloma, although its impact in the context of…”
Get full text

Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation by Rawstron, Andy C., Davies, Faith E., DasGupta, Ranjit, Ashcroft, A. John, Patmore, Russell, Drayson, Mark T., Owen, Roger G., Jack, Andrew S., Child, J. Anthony, Morgan, Gareth J.

“…Conventional monitoring strategies for myeloma are not sufficiently sensitive to identify patients likely to benefit from further therapy immediately after…”
Get full text

A Gene Expression―Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment by PING WU, WALKER, Brian A, BREWER, Daniel, GREGORY, Walter M, ASHCROFT, John, ROSS, Fiona M, JACKSON, Graham H, CHILD, Anthony J, DAVIES, Faith E, MORGAN, Gareth J

“…Myeloma bone disease impairs quality of life and is associated with impaired survival. Even with effective bisphosphonate treatment, a significant proportion…”
Get full text

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis by Munshi, Nikhil C, Avet-Loiseau, Herve, Rawstron, Andy C, Owen, Roger G, Child, J Anthony, Thakurta, Anjan, Sherrington, Paul, Samur, Mehmet Kemal, Georgieva, Anna, Anderson, Kenneth C, Gregory, Walter M

“…Numerous studies have evaluated the prognostic value of minimal residual disease (MRD) in patients with multiple myeloma (MM). Most studies were small and…”
Get more information